Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: A Secondary Analysis of HPTN 083

By sjmartinez • November 24, 2024

Clement ME, Hanscom B, Haines D, Bazan JA, Chotirosniramit N, Kofron R, Mannheimer S, Mayer KH, Torres Silva MS, Soto-Torres L, Rinehart AR, Rooney JF, Jennings A, Gomez-Feliciano K, McCauley M, Grinsztejn B, Landovitz RJ; for HPTN 083 Study Team. Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: A Secondary Analysis of HPTN 083. Clin Infect Dis. 2024 Nov 23:ciae572. doi: 10.1093/cid/ciae572. Epub ahead of print. PMID: 39579334.

Tags: bacterial sexually transmitted infections, CAB-LA, efficacy, HIV prevention, Infectious Diseases, Long-acting PrEP, Publications

Single-cell analyses identify monocyte gene expression profiles that influence HIV-1 reservoir size in acutely treated cohorts

Ehrenberg PK, Geretz A, Volcic M, Izumi T, Yum LK, Waickman A, Shangguan S, Paquin-Proulx D, Creegan M, Bose M, Machmach K, McGraw A, Narahari[...]

HIV-Superinfection in Kidney Transplant Recipients with HIV who Received Organs from Donors with HIV

Rozek GM, Yang P, Eby Y, Benner SE, Martens C, Habtehyimer F, Chahoud M, Brown D, Desai NM, Florman S, Rana MM, Pereira MR, Hand[...]

Factors associated with cervical cancer screening: results from cross-sectional surveys in Kenya and Malawi

Moucheraud C, Chibaka S, Golub G, Kalande P, Makwaya A, Ochieng E, Ogutu V, Phiri K, Phiri S, Hoffman RM. Factors associated with cervical cancer[...]